Organization

Thermo Fisher Scientific Inc.

8 members

What's driving coverage of Thermo Fisher Scientific Inc. right now?

Corporate ratings

High Risk

Thermo Fisher was rated high risk because it scored poorly across governance categories, including discriminatory philanthropy, employment protection, advocacy bias, funding, and political actions. The company is seen as prioritizing identity-based and partisan initiatives over merit-based business practices, which the report argues undermines free speech, free enterprise, and shareholder interests.

CancellationsMedium Risk
Discriminatory PhilanthropyHigh Risk
Employment ProtectionHigh Risk
Advocacy BiasHigh Risk
FundingHigh Risk
Political ActionsHigh Risk

Board Bias

8 members

Comments

Ask this entity anything:

Free account · your comment posts right after signup

Business
ImmuPharma Selects Thermo Fisher CDMO for Kapiglucagon
ImmuPharma has named Thermo Fisher Scientific’s Patheon as the drug product CDMO for Kapiglucagon, following the earlier selection of Bachem for API manufacturing, as it pushes the glucagon prodrug toward IND-enabling development for Type 1 diabetes and potential dual-hormone artificial pancreas applications. The company is pursuing a streamlined regulatory path, potentially a 505(b)(2) in the U.S., with plans to file an IND and begin first-in-human studies subject to regulatory confirmation.
5 sources

Thermo Fisher Scientific Inc.

Corporate ratings

Comments

ImmuPharma Selects Thermo Fisher CDMO for Kapiglucagon

Thermo Fisher Scientific Inc.

Overview

Corporate ratings

Comments

ImmuPharma Selects Thermo Fisher CDMO for Kapiglucagon

Thermo Fisher Scientific Inc. across IJR

Overview

Thermo Fisher Scientific Inc. across IJR